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A B S T R A C T
Purpose
The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the
addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low
tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the
primary efﬁcacy analysis.
Patients and Methods
Eligible patients had ovarian carcinoma that progressed during or within 6 months of completing four or
more platinum cycles, centrally tested low tumor HER3 mRNA expression (concentration ratio # 2.81
by quantitative reverse transcriptase polymerase chain reaction on cobas z480 [Roche Molecular
Diagnostics, Pleasanton, CA]), and no more than two prior lines of chemotherapy. After investigators’
selection of the chemotherapy backbone (single-agent topotecan, weekly paclitaxel, or gemcitabine), pa-
tients were randomly assigned to also receive either placebo or pertuzumab (840-mg loading dose followed
by 420mg every 3weeks). Stratiﬁcation factors were selected chemotherapy, prior antiangiogenic therapy,
and platinum-free interval. The primary end point was independent review committee–assessed
progression-free survival (PFS). Additional end points included overall survival, investigator-assessed PFS,
objective response rate, safety, patient-reported outcomes, and translational research.
Results
Overall, 156 patientswere randomly assigned. Adding pertuzumab to chemotherapy did not signiﬁcantly
improve independent review committee–assessed PFS for the primary analysis (stratiﬁed hazard ratio,
0.74; 95% CI, 0.50 to 1.11; P = .14; median PFS, 4.3 months for pertuzumab plus chemotherapy v
2.6 months for placebo plus chemotherapy). Sensitivity analyses and secondary efﬁcacy end point
results were consistent with the primary analysis. The effect on PFS favoring pertuzumab was more
pronounced in the gemcitabine and paclitaxel cohorts. No new safety signals were seen.
Conclusion
Although the primary objectivewas notmet, subgroup analyses showed trends in PFS favoring pertuzumab
in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer.
J Clin Oncol 34. © 2016 by American Society of Clinical Oncology
INTRODUCTION
The humanized monoclonal antibody pertuzumab
is an established standard of care in human epi-
dermal growth factor receptor (HER) 2–positive
metastatic breast cancer, signiﬁcantly improving
progression-free survival (PFS) and overall survival
(OS) when combined with anti-HER2 therapy
and chemotherapy.1-3 Pertuzumab inhibits HER2
binding with HER family members (HER1, HER3,
and HER4). The HER2/HER3 heterodimer is
the most potent in HER signaling,4 resulting in
activation of various downstream signal trans-
duction pathways (including PI3K) and possible
© 2016 by American Society of Clinical Oncology 1
 http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.66.0787The latest version is at 
Published Ahead of Print on June 6, 2016 as 10.1200/JCO.2015.66.0787
 Copyright 2016 by American Society of Clinical Oncology
134.58.179.36
Information downloaded from jco.ascopubs.org and provided by at KU Leuven University Library on June 13, 2016 from
Copyright © 2016 American Society of Clinical Oncology. All rights reserved.
downregulation of HER3 mRNA.5,6 In ovarian cancer (OC) cell
lines, pertuzumab reversed this downregulation.5,7
Two randomized phase II trials evaluated pertuzumab combined
with chemotherapy in OC, one in platinum-sensitive OC8 and one in
platinum-resistant OC (PROC; TOC3258g).5 Neither trial met its
primary objective of signiﬁcantly improving PFS in the overall pop-
ulation. However, in PROC, retrospective subgroup analyses dem-
onstrated signiﬁcantly improved PFSwith pertuzumab in patients with
low (below the study population median) tumor HER3 mRNA ex-
pression (PFS hazard ratio [HR], 0.32; 95% CI, 0.17 to 0.59; median
PFS, 5.3 months with pertuzumab v 1.4 months with placebo).5 Low
HER3 mRNA expression also seemed to be associated with a partic-
ularly poor prognosis (median PFS with placebo plus gemcitabine:
1.4months in patients with lowHER3mRNA expression v 5.5months
in thosewith high expression). A similar but lessmarked predictive and
prognostic effect was seen in platinum-sensitive OC in the subgroup
with shorter treatment-free intervals.8
These observations led to the design of the two-part Arbeits-
gemeinschaft Gyna¨kologische Onkologie Ovarian Cancer Study
Group (AGO-OVAR) 2.20/European Network for Gynecological
Oncological Trial Groups (ENGOT) ov14/PENELOPE trial (Pertu-
zumab in Platinum-Resistant Low HER3 mRNA Epithelial Ovarian
Cancer; ClinicalTrials.gov identiﬁer: NCT01684878). Part 1 was
a nonrandomized run-in phase to assess the safety of combining
pertuzumab with either weekly paclitaxel or topotecan. Gemcitabine
was not included because its tolerability with pertuzumab was pre-
viously established in the randomized TOC3258g trial.5 In part 1 of
PENELOPE, no new safety signals were seen when pertuzumab was
combined with either topotecan or weekly paclitaxel; both combi-
nations were tolerable and feasible.9 Therefore, the trial proceeded to
part 2, a prospectively randomized evaluation of chemotherapy with
or without pertuzumab, reported here.
PATIENTS AND METHODS
Study Design
PENELOPE was a placebo-controlled double-blind multinational
randomized phase III trial evaluating pertuzumab combined with the
investigator’s chosen chemotherapy. Before random assignment, in-
vestigators selected the backbone chemotherapy regimen for each patient
(topotecan, weekly paclitaxel, or gemcitabine). Thereafter, patients were
randomly assigned to receive either placebo or pertuzumab with the se-
lected chemotherapy. Recruitment to each chemotherapy cohort was
capped to ensure similar sample sizes. The stratiﬁcation factors were as
follows: selected chemotherapy, prior antiangiogenic therapy (yes v no),
and platinum-free interval (PFI; , 3 v 3 to 6 months).
The primary end point was PFS as assessed by an independent review
committee (IRC). PFS was deﬁned as the interval between random as-
signment and disease progression according to Response Evaluation
Criteria in Solid Tumors (RECIST; version 1.1) or malignant bowel ob-
struction (Appendix, online only) diagnosed in the setting of CA-125
progression, or death, whichever occurred ﬁrst.
OS was a key secondary end point and part of a closed statistical
testing procedure. Additional secondary end points included investigator-
assessed PFS (including malignant bowel obstruction), objective response
rate (ORR; best response according to RECIST 1.1 conﬁrmed $ 4 weeks
after the ﬁrst recorded response) in patients with measurable disease,
clinical beneﬁt rate (CBR; complete or partial response or stable disease
maintained for $ 42 days), safety, tolerability, and patient-reported
outcomes.
Patient Population
Eligible patients had platinum-resistant or platinum-refractory ep-
ithelial ovarian, primary peritoneal, or fallopian tube carcinoma (pro-
gression during platinum therapy or within 6 months of completing four
or more cycles of platinum-containing therapy) and low tumor HER3
mRNA expression. HER3 mRNA expression was assessed using quanti-
tative reverse transcriptase polymerase chain reaction on cobas z480
(Roche Molecular Diagnostics, Pleasanton, CA). Low HER3 mRNA ex-
pression was deﬁned as a concentration ratio# 2.81, corresponding to the
0.71 cutoff value on the LightCycler 2.0 (Roche Diagnostics) platform used
in TOC3258g.5 The conversion formula transforming the cutoff to the new
platform was determined in measurement equivalence studies.
Patients had to have at least one measurable or nonmeasurable
lesion according to RECIST 1.1, an Eastern Cooperative Oncology
Group performance status # 2, left ventricular ejection fraction $
50%, and be aged$ 18 years old. Key exclusion criteria were as follows:
more than two prior lines of chemotherapy, ongoing grade $ 2 pe-
ripheral neuropathy at baseline (paclitaxel cohort only), inadequate
organ function, or uncontrolled hypertension or clinically signiﬁcant
cardiovascular disease.
All patients provided written informed consent before undergoing
any study-speciﬁc procedures. The trial conformed to the Declaration of
Helsinki and Good Clinical Practice guidelines and was approved by the
ethics committee of each participating site.
Treatment
Investigators selected one of the following intravenous chemotherapy
options for each patient: topotecan 1.25 mg/m2 on days 1 to 5 every
3 weeks; paclitaxel 80 mg/m2 on days 1, 8, and 15 every 3 weeks; or
gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks. Premedication
was given according to local practice. Pertuzumab or placebo was ad-
ministered intravenously every 3 weeks at a loading dose of 840 mg on day
1, followed by 420 mg on day 1 of each subsequent cycle. Pertuzumab/
placebo and chemotherapy were continued until disease progression,
unacceptable toxicity, consent withdrawal, or death, whichever occurred
ﬁrst.
Study Assessments
A formalin-ﬁxed parafﬁn-embedded tumor block from each patient
was submitted to a central laboratory for HER3 mRNA eligibility
screening. Tumors were assessed by computed tomography or magnetic
resonance imaging at baseline (within 28 days before the ﬁrst dose), and
then every 9 weeks until disease progression determined by the investigator
using the same imaging method as at baseline. Additional tumor as-
sessments were performed if disease progression was suspected between
scheduled assessments. An IRC (blinded to treatment assignment)
reviewed all radiographic and other tumor assessment data from all pa-
tients to assess responses. Adverse events (AEs) were monitored contin-
uously and recorded from the ﬁrst dose until the safety follow-up visit
28 days after treatment discontinuation. AEs were graded according to the
National Cancer Institute Common Terminology Criteria for Adverse
Events (version 4.0). Hematology and biochemistry tests, CA-125 levels,
and coagulation tests were performed at baseline, before every cycle, and at
the safety follow-up visit. Left ventricular ejection fraction was assessed
within 28 days before the ﬁrst dose and then every 9 weeks, ideally by
echocardiogram or otherwise by multigated acquisition scan, using the
same technique throughout the study. Standard 12-lead ECG assessments
were performed at screening and then as clinically indicated. An In-
dependent Data Monitoring Committee reviewed unblinded safety data
regularly to monitor patient safety.
Statistical Design and Analysis
The planned part 2 sample size was 154 randomly assigned patients to
ensure 140 evaluable patients (70 patients per treatment arm), assuming
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a 10% dropout rate. The primary PFS analysis was prespeciﬁed after
109 IRC-assessed PFS events. This provided 95% power to detect a PFS
HR of 0.50 (median PFS increased from 1.4 to 2.8 months with
pertuzumab added to chemotherapy) with a two-sided a = .05 (log-
rank test). Assumptions were on the basis of results in a subset of
patients with low (below median) tumor HER3 mRNA expression in
TOC3258g.5
Because a slight delay between an investigator-recorded PFS event
and prospective IRC assessment is unavoidable, it was foreseen that at the
primary analysis, more than 109 IRC-assessed PFS events would have
occurred. Consequently, one of the prespeciﬁed sensitivity analyses was on
the basis of the ﬁrst 109 IRC-assessed PFS events.
The trial had 80% power for OS (key secondary end point) using
a closed-test procedure to adjust the signiﬁcance level for multiple sta-
tistical testing. The ﬁnal OS analysis is planned after 129 deaths. An interim
OS analysis was prespeciﬁed at the time of the primary PFS analysis
(boundaries presented in Appendix Table A1, online only).
PFS and OS were estimated using the Kaplan-Meier method. P values
for the stratiﬁed log-rank test (using randomization stratiﬁcation factors)
were calculated. In addition, HRs and associated 95% CIs were calculated
using the Cox regression model. The proportions of responders for ORR
and CBR and the differences between treatments were calculated with
associated 95% Clopper-Pearson CIs.
Efﬁcacy analyses were performed on the intent-to-treat pop-
ulation (all randomly assigned patients). Safety analyses were per-
formed on the safety population (all patients who received at least one
dose of study therapy).
RESULTS
Patient Population
HER3 mRNA eligibility criteria were met in 207 (68%) of 306
patients with valid reverse transcriptase polymerase chain reaction
results (Fig 1). Of these, 156 patients from 52 European centers
were randomly assigned between October 2, 2013, and September
18, 2014. Three patients did not receive randomly assigned
treatment; thus, the safety population included 153 patients (77
patients received pertuzumab plus chemotherapy; 76 patients
received placebo plus chemotherapy). The gemcitabine cohort was
the ﬁrst to be fully recruited (March 2014), followed by paclitaxel
(May 2014), and ﬁnally topotecan (September 2014).
Baseline characteristics were generally well balanced between
treatment arms (Table 1). Comparison of baseline characteristics
according to investigator-selected chemotherapy revealed some
imbalances both between and within chemotherapy cohorts
(Appendix Table A2, online only).
Treatment Exposure
At the data cutoff for the primary PFS analysis (January 30,
2015), the median duration of pertuzumab treatment was
Allocated to placebo + chemotherapy
  Received allocated intervention
(n = 78)
(n = 76)
  Did not receive allocated intervention (n = 2)†
Discontinued intervention
Treatment ongoing
  Placebo therapy ongoing
  Chemotherapy ongoing
(n = 72)
(n = 4)
(n = 4)
(n = 2)§
Analyzed for efficacy
Analyzed for safety
Excluded from safety analysis
(n = 78)
(n = 76)
(n = 2)
Assessed for eligibility (N = 324)
Patients randomly allocated (n = 156)
Excluded
  Not centrally tested
  Invalid test results
  HER3 ineligible
  HER3 eligible but ineligible
    for other reasons
(n = 51)
(n = 7)
(n = 11)
Allocated to pertuzumab + chemotherapy
  Received allocated intervention
  Did not receive allocated intervention
(n = 78)
(n = 77)
(n = 1)*
(n = 168)
(n = 99)
Discontinued intervention
Treatment ongoing
  Pertuzumab therapy ongoing
  Chemotherapy ongoing
(n = 70)
(n = 7)
(n = 7)
(n = 5)‡
Analyzed for efficacy
Analyzed for safety
Excluded from safety analysis
(n = 78)
(n = 77)
(n = 1)
Fig 1. CONSORT diagram. HER3, human
epidermal growth factor receptor 3. (*)
Patient died before starting treatment. (†)
Both patients withdrew consent before
starting treatment. (‡) Three patients on
topotecan, one on paclitaxel, and one on
gemcitabine. (§) One patient on topotecan
and one on paclitaxel.
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3.3 months (range,, 0.1 to 14.5 months) in the pertuzumab plus
chemotherapy arm, and the median duration of placebo treat-
ment was 2.2 months (range, , 0.1 to 10.6 months) in the
placebo plus chemotherapy arm. In both treatment arms, the
most common reason for discontinuing either study therapy was
disease progression.
Efficacy
The median duration of follow-up was 10.3 months in the
pertuzumab plus chemotherapy arm and 10.1 months in the
placebo plus chemotherapy arm. IRC-assessed PFS events were
reported in 66 patients (85%) and 60 patients (77%) receiving
pertuzumab and placebo, respectively. Adding pertuzumab
to chemotherapy did not statistically signiﬁcantly improve
IRC-assessed PFS (stratiﬁed HR, 0.74; 95% CI, 0.50 to 1.11;
two-sided log-rank test, P = .14; Fig 2A). Median PFS was
4.3 months with pertuzumab plus chemotherapy compared
with 2.6 months with placebo plus chemotherapy. Investigator-
assessed PFS showed consistent results (Fig 2B). The concor-
dance rate between IRC- and investigator-assessed PFS status
was 95% in the pertuzumab plus chemotherapy arm and 88%
in the placebo plus chemotherapy arm (Appendix Table A3,
online only).
Sensitivity analyses supported the primary PFS analysis,
with all showing the same direction of effect (Appendix Fig A1,
online only). Notably, in the sensitivity analysis after 109 IRC-
assessed PFS events, the stratiﬁed HR was 0.61 (95% CI, 0.39 to
0.94).
The interim OS analysis, which included 64% of the events
required for the ﬁnal OS analysis, showed no statistically sig-
niﬁcant difference between treatment arms (Fig 3). Response
was evaluable in 130 patients (61 patients in pertuzumab plus
chemotherapy arm and 69 patients in placebo plus chemo-
therapy arm). There was no signiﬁcant difference in either IRC-
or investigator-assessed ORR between the treatment arms (Fig 4).
IRC-assessed CBR was signiﬁcantly higher with pertuzumab
plus chemotherapy than placebo plus chemotherapy; however,
a corresponding difference in investigator-assessed CBR was not
observed (Fig 4).
Subgroup analyses of PFS suggested diverging treatment
effects according to the chemotherapy partner (Fig 5). The di-
rection of effect in the gemcitabine and paclitaxel cohorts favored
pertuzumab, but this was not observed with topotecan. Never-
theless, the treatment-by-chemotherapy interaction P value for
PFS was P = .16. The direction of effect for IRC-assessed CBR
favored pertuzumab in all three chemotherapy cohorts and was
most pronounced with paclitaxel (Fig 4).
A more pronounced pertuzumab effect on PFS was ob-
served in patients who had not received prior antiangiogenic
therapy compared with those exposed to antiangiogenic agents
(Fig 5), but P = .14 for the treatment-by-subgroup interaction.
For PFI, there seemed to be a differential effect on treatment
(interaction P = .02), with a PFS beneﬁt from pertuzumab in
patients with a PFI of 3 to 6 months (platinum-resistant co-
hort) but not in those with a PFI of , 3 months (platinum-
refractory cohort).
Table 1. Summary of Baseline Characteristics by Treatment Arm
Characteristic
Pertuzumab +
Chemotherapy
(n = 78)
Placebo +
Chemotherapy
(n = 78)
No. of
Patients %
No. of
Patients %
Age, years
Median 65 64
Range 32-79 26-80
. 65 38 48.7 34 43.6
. 75 4 5.1 6 7.7
ECOG performance status
0 41 52.6 38 48.7
1 31 39.7 31 39.7
2 5 6.4 9 11.5
3 1 1.3 0 0
Prior second-line chemotherapy 41* 52.6* 48 61.5
FIGO stage
I 4 5.1 3 3.8
II 4 5.1 5 6.4
III 45 57.7 47 60.3
IV 25 32.1 21 26.9
Missing 0 0 2 2.6
Selected chemotherapy†
Topotecan 25 32.1 24 30.8
Paclitaxel 26 33.3 28 35.9
Gemcitabine 27 34.6 26 33.3
Histology
Serous 60 76.9 60 76.9
Endometrioid 2 2.6 6 7.7
Clear cell 6 7.7 4 5.1
Mucinous 0 0 1 1.3
Adenocarcinoma (NOS) 6 7.7 5 6.4
Other 8 10.3 5 6.4
Mixed 2 2.6 2 2.6
Origin of cancer
Ovary 70 89.7 70 89.7
Fallopian tube 6 7.7 3 3.8
Primary peritoneal 5 6.4 11 14.1
Undetermined 1 1.3 0 0
Grade
1 6 7.7 2 2.6
2 12 15.4 13 16.7
3 54 69.2 52 66.7
Missing 6 7.7 11 14.1
Outcome of initial surgery
No macroscopic residual
disease
42 53.8 37 47.4
Macroscopic residual disease 27 34.6 29 37.2
Missing 2 2.6 1 1.3
No surgery 7 9.0 11 14.1
Previous antiangiogenic
therapy†
27 34.6 30 38.5
Previous bevacizumab 19 24.4 23 29.5
Platinum-free interval, months†
, 3 19 24.4 21 26.9
3-6 59 75.6 57 73.1
Measurable disease at baseline 61 78.2 69 88.5
Ascites at baseline 18 23.1 25 32.1
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FIGO, In-
ternational Federation of Gynecology and Obstetrics; NOS, not otherwise
speciﬁed.
*Third line in two patients and fourth line in one patient.
†Stratiﬁcation factor (on the basis of interactive Web- and voice-response
system).
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Safety
The most common AEs (all grades) with pertuzumab
plus chemotherapy were diarrhea, fatigue/asthenia, nausea,
neutropenia, and anemia, and the most common AEs with
placebo plus chemotherapy were fatigue/asthenia, nausea, and
anemia (Table 2). Grade $ 3 AEs were slightly less frequent
with pertuzumab plus chemotherapy (69%) than placebo plus
chemotherapy (75%). Compared with placebo plus chemo-
therapy, pertuzumab-containing therapy was associated with
an increased incidence of diarrhea (all grades and grade $ 3)
and grade$ 3 neutropenia and slightly more grade$ 3 nausea
and vomiting, but less frequent constipation, grade $ 3 in-
testinal obstruction, and grade $ 3 fatigue/asthenia. AEs
resulted in death in six patients (8%) receiving pertuzumab
plus chemotherapy (three as a result of OC, two unexplained
deaths, and one as a result of general physical health de-
terioration) and 10 patients (13%) receiving placebo plus
chemotherapy (two as a result of intestinal obstruction and
one each as a result of cerebral ischemia, hydrocephalus, acute
myocardial infarction, encephalitis, pleural effusion, general
physical health deterioration, performance status decreased,
and OC). Pertuzumab/placebo was discontinued because of
AEs in six patients (8%) receiving pertuzumab plus chemo-
therapy and 14 patients (18%) receiving placebo plus che-
motherapy. Subgroup analyses of safety by chemotherapy
cohort were generally consistent with the recognized safety
proﬁles of the backbone chemotherapy (Appendix Table A4,
online only).
Biomarkers
To explore potential differential beneﬁt according to HER3
mRNA expression further, we conducted subgroup analyses ap-
plying HER3 mRNA cutoffs at the median and quartiles. Within
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(n = 78)
PER-CT
(n = 78)
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Fig 2. Progression-free survival (PFS), in-
cluding malignant bowel obstruction, as
assessed by (A) independent review com-
mittee (primary end point) and (B) in-
vestigators (secondary end point). HR, hazard
ratio; PER-CT, pertuzumab plus chemother-
apy; PLA-CT, placebo plus chemotherapy. (*)
Malignant bowel obstruction criteria in one
patient.
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the preselected low tumor HER3 mRNA–expressing population
treated in this study, the PFS HR was 0.79 (95% CI, 0.48 to 1.33) in
patients with HER3 mRNA expression less than the median cutoff
value and 0.68 (95%CI, 0.42 to 1.12) in patients with HER3mRNA
expression greater than the median cutoff value (interaction
P = .68). In the control arm, median PFS durations were 2.7 and
2.6 months for low and high HER3 mRNA subgroups, re-
spectively. Quartile analyses revealed no further consistent
Events, No. (%)
Median OS, months
(95% CI)
HR (stratified)
(95% CI)
Two-sided log-rank P 
39 (50.0)
PER-CT
(n = 78)
43 (55.1)
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.44 
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(n = 78)
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78 73 63 53 44 24 11PLA-CT 67 61 45 32 18 5 2 1 1
2 4 6 8
Time (months)
Es
tim
at
ed
 P
ro
ba
bi
lit
y
10 12 14 16
Fig 3. Interim overall survival (OS; key
secondary end point). HR, hazard ratio; NR, not
reached; PER-CT, pertuzumab plus chemo-
therapy; PLA-CT, placebo plus chemotherapy.
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Fig 4. Objective response rate (ORR) and clinical beneﬁt rate (CBR) in patients withmeasurable disease. Numbers above bars show difference between treatment arms.
Numbers in parentheses show approximate 95%CIs for the difference between the two rates using Hauck-Anderson method. IRC, independent review committee; PER-
CT, pertuzumab plus chemotherapy; PLA-CT, placebo plus chemotherapy.
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differential beneﬁt according to HER3 mRNA expression (Appendix
Fig A2, online only).
DISCUSSION
AGO-OVAR 2.20 (PENELOPE) is one of the ﬁrst trials in PROC in
which the study cohort was selected by a biomarker identiﬁed in
exploratory analyses of prior phase II studies. Combining pertuzumab
with chemotherapy in these patients did not statistically signiﬁcantly
improve IRC-assessed PFS (primary end point; HR, 0.74; 95%CI, 0.50
to 1.11; P = .14), although there was a numerical trend favoring the
pertuzumab arm. This may be because the thresholds were over-
ambitious on the basis of overoptimistic exploratory analyses deﬁning
the biomarker cutoff and suggesting a strong predictive effect of the
biomarker for efﬁcacy. On the basis of these assumptions, the sample
size calculations led to a rather small phase III population heavily
dependent on exactly repeating the effect observed in the exploratory
model. Nevertheless, results for secondary end points (ORR, CBR,
investigator-assessed PFS, and interim OS) were consistent with the
primary analysis, as were sensitivity analyses.
Although neither IRC-assessed nor investigator-assessed PFS
comparisons reached statistical signiﬁcance, the effect of pertu-
zumab seemed larger in the former analysis. There was some
discordance between IRC and investigator assessment of PFS, with
greater disparity observed in the placebo plus chemotherapy arm
than the pertuzumab plus chemotherapy arm. This contrasts with
previous reports comparing IRC- and investigator-assessed PFS in
phase III trials in OC.10-13
Another interesting observation is the suggested diverging
effects according to chemotherapy partner, with PFS trends fa-
voring pertuzumab in the gemcitabine and paclitaxel cohorts, but
not the topotecan cohort. There is no clear biologic explanation for
a more pronounced effect of pertuzumab with gemcitabine and
paclitaxel than with topotecan. Importantly, the trial was not
designed to assess efﬁcacy in the individual chemotherapy cohorts
or to compare efﬁcacy between chemotherapy regimens. Che-
motherapy selection was at the discretion of the investigators and
was, therefore, likely inﬂuenced by patient and disease charac-
teristics and prior treatment, which showed some imbalances both
within and between chemotherapy cohorts. The apparent lack of
effect of combining pertuzumab with topotecan should be treated
with some caution given the small sample size and the exploratory
nature of this subgroup analysis (although chemotherapy choice
was a stratiﬁcation factor). However, it does perhaps help to ex-
plain the lack of effect in the overall population and raises the
question of whether pertuzumab merits further evaluation with
paclitaxel or gemcitabine in selected patient populations.
Factor
All
Selected
chemotherapy 
Prior antiangiogenic
therapy†
Platinum-free
interval, months 
Subgroup
Gemcitabine
Paclitaxel
Topotecan
No. of Events/
Patients (%)
Median PFS
(months)
HR (95% CI)*
0.2 0.5 1 2 4
HR
(95% CI)*
0.75 (0.52 to 1.07)
0.63 (0.34 to 1.14)
0.56 (0.29 to 1.09)
1.19 (0.63 to 2.25)
PER-CT
66/78
(85)
24/27
(89)
20/26
(77)
22/25
(88)
PER-CT
4.3
4.3
6.4
2.8
PER-CT
BetterPLA-CT
2.6
2.1
4.2
2.7
PLA-CT
BetterPLA-CT
60/78
(77)
21/26
(81)
21/28
(75)
18/24
(75)
Yes
No
1.10 (0.61 to 1.99)
0.63 (0.40 to 0.98)
22/27
(81)
44/51
(86)
3.7
4.4
2.2
2.7
22/30
(73)
38/48
(79)
< 3
3–6
1.61 (0.79 to 3.29)
0.61 (0.40 to 0.92)
18/19
(95)
48/59
(81)
3.5
5.3
3.4
2.6
13/21
(62)
47/57
(82)
Fig 5. Subgroup analyses of independent review committee–assessed progression-free survival (PFS; including malignant bowel obstruction) according to stratiﬁcation
factors (according to interactive Web- and voice-response system). HR, hazard ratio; PER-CT, pertuzumab plus chemotherapy; PLA-CT, placebo plus chemotherapy. (*)
Unstratiﬁed analysis. (†) Patients who had participated in a blinded trial of an antiangiogenic agent were enrolled onto the same stratum as those who were known to have
received previous antiangiogenic therapy.
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A signiﬁcant PFS improvement with pertuzumab was ob-
served in patients with a PFI of 3 to 6 months but not in patients
with a PFI of , 3 months. Although the interaction P value in-
dicated a signiﬁcant impact of PFI on treatment effect, the small
sample sizes must be considered before drawing conclusions from
this observation. Nevertheless, it is interesting that imbalances
between chemotherapy cohorts with respect to PFI favored per-
tuzumab in the gemcitabine cohort and favored placebo in the
topotecan cohort.
When the PENELOPE trial was designed, pegylated liposomal
doxorubicin could not be included as one of the three chemo-
therapy options because of ongoing supply issues. Therefore,
topotecan, which is widely used in some countries, was chosen as
an alternative. More recently, perceptions regarding the efﬁcacy of
topotecan have been challenged by exploratory analyses of the
Avastin Use in Platinum-Resistant Epithelial Ovarian Cancer
(AURELIA) trial,14 which evaluated the addition of bevacizumab to
chemotherapy for PROC. In AURELIA, as in PENELOPE, che-
motherapy choice was at the investigator’s discretion, and com-
parisons of nonrandomized chemotherapy cohorts have obvious
limitations. Nevertheless, it has been suggested that topotecan
may be a suboptimal chemotherapy option in PROC.15 In both
PENELOPE and AURELIA, topotecan alone demonstrated dis-
appointing PFS and especially ORR. However, in contrast to
PENELOPE, both PFS and ORR were signiﬁcantly improved by
adding bevacizumab to topotecan in AURELIA (PFS: HR, 0.32;
95% CI, 0.21 to 0.49; ORR: 0% with topotecan alone v 17% with
topotecan plus bevacizumab). The ﬁnal OS analysis of our trial
(planned after 129 deaths) may provide greater insight into dif-
ferences between chemotherapy cohorts.
In subgroup analyses of the TOC3258g trial according to
HER3 mRNA expression quartile, patients with the lowest tumor
HER3 mRNA expression gained greatest beneﬁt from pertuzumab,
with a linear relationship between magnitude of treatment effect
and HER3 mRNA expression level.16 Quartile analyses of the
present trial according to HER3 mRNA expression did not conﬁrm
the linear trend observed in TOC3258g. Results were inconsistent,
with the greatest pertuzumab effect seen in patients in the lowest
and highest quartiles. However, PENELOPE was not designed
either to test HER3 mRNA as a predictive biomarker or to validate
the cutoff value deﬁning low HER3 mRNA expression.
Pertuzumab seemed to be well tolerated with all chemo-
therapy partners, and there were no new safety signals. Diarrhea
was more common with pertuzumab-containing therapy, con-
sistent with previous experience in breast cancer and OC. Grade$
3 neutropenia was also more common, as in the TOC3258g trial,5
but otherwise, there was little evidence of additive toxicity with
pertuzumab-containing combination therapy.
In the two chemotherapy cohorts showing the most prom-
ising effect, HR point estimates were 0.63 (gemcitabine) and 0.56
(paclitaxel), making the ambitious target HR of 0.50 for this patient
population even more debatable. These ﬁndings should be con-
sidered when designing future trials in this patient population.
In conclusion, although PENELOPE did not meet its primary
objective, the results provide insight into the biology, prognosis,
and management of PROC. These ﬁndings merit further explora-
tion of pertuzumab with carefully selected chemotherapy partners
in OC.
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Table 2. Summary of Safety
Adverse Event*
Pertuzumab +
Chemotherapy
(n = 77)
Placebo +
Chemotherapy
(n = 76)
No. of
Patients %
No. of
Patients %
Diarrhea 52 67.5 23 30.3
Grade $ 3 11 14.3 1 1.3
Fatigue/asthenia 51 66.2 46 60.5
Grade $ 3 6 7.8 9 11.8
Nausea 32 41.6 33 43.4
Grade $ 3 4 5.2 1 1.3
Neutropenia/neutrophil count
decreased
29 37.7 23 30.3
Grade $ 3 24 31.2 16 21.1
Anemia 29 37.7 30 39.5
Grade $ 3 6 7.8 5 6.6
Vomiting 21 27.3 21 27.6
Grade $ 3 4 5.2 2 2.6
Abdominal pain 17 22.1 22 28.9
Grade $ 3 2 2.6 2 2.6
Alopecia 15 19.5 21 27.6
Grade $ 3 1 1.3 1 1.3
Decreased appetite 13 16.9 17 22.4
Grade $ 3 0 0 0 0
Constipation 12 15.6 21 27.6
Grade $ 3 0 0 1 1.3
Leukopenia/WBC count decreased 9 11.7 14 18.4
Grade $ 3 5 6.5 7 9.2
Hypokalemia 9 11.7 5 6.6
Grade $ 3 5 6.5 4 5.3
Thrombocytopenia 4 5.2 6 7.9
Grade $ 3 4 5.2 3 3.9
Hypertension 4 5.2 5 6.6
Grade $ 3 4 5.2 3 3.9
GGT increased 3 3.9 6 7.9
Grade $ 3 2 2.6 4 5.3
Intestinal obstruction 2 2.6 5 6.6
Grade $ 3 1 1.3 5 6.6
Febrile neutropenia 2 2.6 4 5.3
Grade $ 3 2 2.6 4 5.3
NOTE. All grades in$ 20% or grade$ 3 in$ 5% of patients in either treatment
group.
Abbreviation: GGT, g-glutamyl transferase.
*Medical Dictionary for Regulatory Activities preferred terms.
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GLOSSARY TERMS
Biomarker: a functional biochemical or molecular indicator of
a biologic or disease process that has predictive, diagnostic, and/or
prognostic utility.
CA-125 (cancer antigen 125): a protein produced by the fal-
lopian tubes, the endometrium, and the lining of the abdominal cavity
(peritoneum). CA-125 is a tumor marker present in higher than normal
amounts in the blood and urine of patients with certain cancers.
Typically, women with ovarian cancer have high levels of CA-125. Other
conditions associated with elevated levels of CA-125 include endo-
metriosis, pancreatitis, pregnancy, normal menstruation, and pelvic
inﬂammatory disease. CA-125 levels may be used to help diagnose
ovarian cancer and to determine whether these tumors are responding
to therapy. The normal range for CA-125 is less than 35 U/mL and less
than 20 U/mL for women who have been treated for ovarian cancer.
Women with ovarian cancer may show values higher than 65 U/mL.
hazard ratios: the ratio of the hazard rate in one group (for ex-
ample, a group of treated patients) to the hazard rate in another group
(for example, an untreated control group of patients). The hazard rate is
the probability of a speciﬁed event, such as death or cancer recurrence,
occurring during a short time interval. The hazard ratio, therefore, is
a measure of the relative probability of an event occurring at any given
point in time.
overall survival: the duration between random assignment and
death.
Pertuzumab: a humanized monoclonal antibody that binds to
HER2 at a site used by the receptor to form dimers with other receptors
(the dimerization site) belonging to this family. Signaling via all HER2
dimers is, therefore, inhibited. Also referred to as Omnitarg. See HER2/
neu (human epidermal growth factor receptor 2) and ERBB2.
progression-free survival: time from random assignment until
death or ﬁrst documented relapse, categorized as either locoregional
(primary site or regional nodes) failure or distant metastasis or death.
RECIST (Response Evaluation Criteria in Solid
Tumors): a model proposed by the Response Evaluation Criteria
Group by which a combined assessment of all existing lesions, char-
acterized by target lesions (to be measured) and nontarget lesions, is
used to extrapolate an overall response to treatment.
stratiﬁcation factor: a factor used to separate data into subgroups to
determine whether that factor is signiﬁcant; subgroup analysis is an analysis
in which the intervention effect is evaluated in a deﬁned subset of the
participants in the trial or in complementary subsets, such as by sex or in age
categories. Sample sizes in subgroup analyses are often small and subgroup
analyses therefore usually lack statistical power. Comparison of subgroups
should be done by test of interaction rather than by comparison of P values.
They are also subject to the multiple comparisons problem, which increases
the probability of making a type I error (ie, attributing a difference to an
intervention when chance is the more likely explanation).
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Appendix
Malignant Bowel Obstruction Criteria
Assessment of abdominal symptoms indicative of malignant bowel obstruction. If cancer antigen (CA) –125 progression was
diagnosed, the following abdominal symptoms indicative of malignant bowel obstruction (MBO) were assessed and documented in
the electronic case report form (eCRF): abdominal pain, nausea, vomiting, abdominal distension, constipation, and diarrhea.
If one of these abdominal symptoms was new or had worsened by at least one grade (National Cancer Institute Common
Terminology Criteria for Adverse Events), it was considered present. In this case, the complete set of diagnostic criteria for MBO
(MBO criteria) were assessed and reported.
Assessment of MBO criteria. If one or more of the abdominal symptoms indicative of MBO listed earlier was present and the
increase in CA-125 fulﬁlled the criteria for CA-125 progression, nonmalignant causes of these symptoms were assessed and
reported in the eCRF to reliably exclude nonmalignant causes of bowel obstruction.
First, there had to be no evidence of metabolic or electrolyte abnormalities that may lead to impaired intestinal motility. If
metabolic abnormalities or electrolyte disturbances were detected that were considered to be causative of the abdominal symptoms
of the patient, MBO could not be diagnosed according to the deﬁnition of this protocol.
Second, the investigator judged the abdominal symptom(s) as described earlier as not related to the investigational medicinal
product (IMP). This could be the case if abdominal symptoms began after a phase of good tolerability of the IMP.
Third, the investigator judged the abdominal symptoms as not related to any concomitant medication (eg, constipation as
a result of 5-hydroxytryptamine-3 receptor antagonists or hyperglycemia as a result of corticosteroids). This may not be the case if
the abdominal symptom concerned is listed as an adverse event in the summary of product characteristics or package insert of the
respective drug or if the abdominal symptoms started shortly after initiation of treatment with the respective drug or an elevation of
dose.
If the investigator judged the abdominal symptom(s) described earlier as related to the IMP or any concomitant medication,
MBO could not be diagnosed according to the deﬁnition of this protocol. In addition, the investigator had to assess that there was
no evidence of any of the following: mechanical obstruction as a result of nonmalignant causes (eg, adhesions, hernia, volvulus);
inﬂammatory causes (eg, diverticulitis, Crohn disease, ulcerous colitis, ischemic colitis, cystitis); or acute abdominal symptoms of
nonmalignant etiology (eg, pancreatitis, cholecystitis, intestinal perforation, intestinal ischemia, intestinal pseudo-obstruction
[Ogilvie syndrome]).
Prior computed tomography imaging was to be (re)assessed for evidence of these and other suspected causes. Further as-
sessments may have been performed and documented in the eCRF to reliably exclude other suspected causes as clinically indicated.
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At a minimum, these assessments were to include the following laboratory parameters: glucose, sodium, potassium, calcium,
magnesium, creatinine, AST, ALT, g-glutamyl transferase, alkaline phosphatase, lipase, lactate dehydrogenase, total bilirubin and
direct bilirubin (if total bilirubin is elevated), blood urea nitrogen, uric acid, total protein (or albumin only), C-reactive protein, and
urine analysis (dipstick). The clinical and laboratory data were to be documented in the eCRF whenever MBO was suspected and
were subjected to central independent review.
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Fig A1. Summary of prespeciﬁed sensitivity analyses of progression-free survival (PFS). HR, hazard ratio; IRC, independent review committee; MBO, malignant bowel
obstruction; PD, progressive disease; PER-CT, pertuzumab plus chemotherapy; PLA-CT, placebo plus chemotherapy. (*) Stratiﬁed analysis.
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Fig A2. Independent review committee–assessed progression-free survival (PFS) according to human epidermal growth factor receptor 3 (HER3) mRNA quartile
(unstratiﬁed analysis). HR, hazard ratio; PER-CT, pertuzumab plus chemotherapy; PLA-CT, placebo plus chemotherapy. (*) Unstratiﬁed analysis.
Table A1. Summary of Planned OS Analyses and the Efﬁcacy Stopping
Boundary
OS Analysis
No. of
Deaths Efﬁcacy Stopping Boundary
Interim analysis at
the time of the PFS
analysis
81 Two-sided P , .0094 (corresponds
to an observed HR of 0.5613)
Final analysis 129 Two-sided P , .0471 (corresponds to
a HR of 0.7049)
Abbreviations: HR, hazard ratio; OS, overall survival; PFS, progression-free
survival.
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Table A3. Concordance Between Investigator-Assessed and IRC-Assessed RECIST PFS Status
RECIST PFS Status by IRC Assessment
RECIST PFS Status by Investigator Assessment, No. (%)
Pertuzumab +
Chemotherapy (n = 78)
Placebo + Chemotherapy
(n = 78) Total (N = 156)
Yes No Yes No Yes No
Yes 64 (82) 2 (3) 60 (77) 0 124 (79) 2 (1)
No 2 (3) 10 (13) 9 (12) 9 (12) 11 (7) 19 (12)
Abbreviations: IRC, independent review committee; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.
Table A2. Baseline Characteristics (as recorded in the CRF) by Chemotherapy Cohort and Treatment Arm
Characteristic
No. of Patients (%)
Gemcitabine Paclitaxel Topotecan
Pertuzumab (n = 27)
Placebo
(n = 25) Pertuzumab (n = 24)
Placebo
(n = 28) Pertuzumab (n = 26)
Placebo
(n = 23)
Prior antiangiogenic therapy
Yes 9 (33) 7 (28) 10 (42) 11 (39) 13 (50) 12 (52)
No 18 (67) 18 (72) 14 (58) 17 (61) 13 (50) 11 (48)
Platinum-free interval, months
, 3 3 (11) 9 (36) 8 (33) 8 (29) 8 (31) 6 (26)
3-6 24 (89) 16 (64) 16 (67) 20 (71) 18 (69) 17 (74)
Age, years
Median (range) 62 (32-79) 66 (26-80) 65 (45-79) 60 (44-78) 65 (43-76) 65 (42-80)
. 65 12 (44) 14 (56) 12 (50) 7 (25) 13 (50) 11 (48)
. 75 2 (7) 3 (12) 1 (4) 1 (4) 1 (4) 2 (9)
ECOG performance status
0 16 (59) 15 (60) 12 (50) 11 (39) 13 (50) 11 (48)
1 9 (33) 8 (32) 11 (46) 13 (46) 10 (38) 10 (43)
2 2 (7) 2 (8) 1 (4) 4 (14) 2 (8) 2 (9)
3 0 0 0 0 1 (4) 0
Baseline serum CA-125
Mean, U/mL 866 1,326 1,211 1,191 941 1,990
$ 23 upper normal limit 24 (89) 20 (80) 17 (71) 25 (89) 20 (77) 20 (87)
Abbreviations: CA, cancer antigen; CRF, case report form; ECOG, Eastern Cooperative Oncology Group.
Table A4. Grade $ 3 Adverse Events by Chemotherapy Cohort and Treatment Arm
Grade $ 3 Adverse Event
No. of Patients (%)
Gemcitabine Paclitaxel Topotecan
Pertuzumab
(n = 27)
Placebo
(n = 25)
Pertuzumab
(n = 24)
Placebo
(n = 28)
Pertuzumab
(n = 26)
Placebo
(n = 23)
Any 18 (66.7) 20 (80.0) 15 (62.5) 20 (71.4) 20 (76.9) 17 (73.9)
Neutropenia/neutrophil count
decreased
10 (37.0) 4 (16.0) 5 (20.8) 4 (14.3) 9 (34.6) 8 (34.8)
Febrile neutropenia 1 (3.7) 0 0 0 1 (3.8) 4 (17.4)
Leukopenia/WBC count decreased 0 0 0 2 (7.1) 5 (19.2) 5 (21.7)
Anemia 2 (7.4) 1 (4.0) 0 1 (3.6) 4 (15.4) 3 (13.0)
Thrombocytopenia 0 0 0 0 4 (15.4) 3 (13.0)
Diarrhea 3 (11.1) 0 5 (20.8) 1 (3.6) 3 (11.5) 0
Vomiting 0 0 3 (12.5) 2 (7.1) 1 (3.8) 0
Asthenia/fatigue 1 (3.7) 2 (8.0) 2 (8.3) 2 (7.1) 3 (11.5) 5 (21.7)
Peripheral neuropathy 0 0 3 (12.5) 1 (3.6) 0 0
Hypertension 1 (3.7) 3 (12.0) 1 (4.2) 0 2 (7.7) 0
General physical health deterioration 0 0 0 1 (3.6) 3 (11.5) 1 (4.3)
Intestinal obstruction 1 (3.7) 3 (12.0) 0 2 (7.1) 0 0
NOTE. Grade $ 3 adverse events in $ 10% of patients in any cohort or treatment arm.
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